Elevated Levels of Neutrophil Gelatinase-Associated Lipocalin in Bile From Patients With Malignant Pancreatobiliary Disease
| Autor: | Simon D. Taylor-Robinson, David Westaby, Christopher A. Wadsworth, Shahid A. Khan, Andrew V. Thillainayagam, Abigail Zabron, Fiona Laird, Verena M Horneffer-van der Sluis, Panagiotis Vlavianos, Robert Edwards, Magdalena Gierula |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty CA-19-9 Antigen Gallstones Disease Lipocalin digestive system Lipocalin-2 Cholestasis Predictive Value of Tests Proto-Oncogene Proteins Biomarkers Tumor medicine Bile Humans Prospective Studies Prospective cohort study Aged Biliary tract neoplasm integumentary system Hepatology business.industry Gastroenterology Acute-phase protein Middle Aged medicine.disease Lipocalins Pancreatic Neoplasms Biliary Tract Neoplasms Pancreatitis ROC Curve Regression Analysis business Acute-Phase Proteins |
| Zdroj: | American Journal of Gastroenterology. 106:1711-1717 |
| ISSN: | 0002-9270 |
| DOI: | 10.1038/ajg.2011.187 |
| Popis: | Accurate differentiation between benign and malignant causes of biliary obstruction remains challenging and reliable biomarkers are urgently needed. Bile is a potential source of such biomarkers. Our aim was to apply a proteomic approach to identify a potential biomarker in bile that differentiates between malignant and benign disease, and to assess its diagnostic accuracy. Neutrophil gelatinase-associated lipocalin (NGAL) is multi-functional protein, released from activated neutrophils, with roles in inflammation, immune function, and carcinogenesis. It has not previously been described in bile.Bile, urine, and serum were collected prospectively from 38 patients undergoing endoscopic retrograde cholangiopancreatography ("discovery" cohort); 22 had benign and 16 had malignant pancreatobiliary disease. Initially, label-free proteomics and immunoblotting were performed in samples from a subset of these patients. Enzyme-linked immunosorbent assay was then performed for NGAL as a potential biomarker on all samples in this cohort. The diagnostic performance of biliary NGAL was then validated in a second, independent group ("validation" cohort) of 21 patients with pancreatobiliary disease (benign n=14, malignant n=7).NGAL levels were significantly raised in bile from the malignant disease group, compared with bile from the benign disease group in the discovery cohort (median 1,556 vs. 480 ng/ml, P=0.007). Biliary NGAL levels had a receiver operating characteristic area under curve of 0.76, sensitivity 94%, specificity 55%, positive predictive value 60%, and negative predictive value 92% for distinguishing malignant from benign causes. Biliary NGAL was independent of serum biochemistry and carbohydrate antigen 19-9 (CA 19-9) in differentiating between underlying benign and malignant disease. No significant differences in serum and urine NGAL levels were found between benign and malignant disease. Combining biliary NGAL and serum CA 19-9 improved diagnostic accuracy for malignancy (sensitivity 85%, specificity 82%, positive predictive value 79%, and negative predictive value 87%). The diagnostic accuracy of biliary NGAL was confirmed in the second independent validation cohort.NGAL in bile is a novel potential biomarker to help distinguish benign from malignant biliary obstruction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|